• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program Original Articles
Conclusions— In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research

Abstract 245: Cost Effectiveness and Safety of Abbreviated Eptifibatide Infusion in Veterans Undergoing Percutaneous Coronary Intervention Session Title: Poster Session II
Conclusion: In this real world cohort of patients undergoing PCI, an abbreviated 2 hour eptifibatide infusion after PCI was safe and had a cost savings of greater than 50% per patient, when compared with a standard 18 hour infusion. This approach is more cost-effective and should be considered in patients undergoing PCI who are not pretreated with dual antiplatelet therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ghadban, R., Shah, A., Ampadu, J., Linneman, T., Thomas, J.-A., Forsberg, M., Stolker, J., Klein, A. Tags: Session Title: Poster Session II Source Type: research